Cheng Lü
Impact in
-
- Traditional Chinese Medicine Studies
- Cancer Research top 1%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Metabolomics and Mass Spectrometry Studies 17
-
- Traditional Chinese Medicine Studies 21
- Natural Compounds in Disease Treatment 17
- Traditional Chinese Medicine Analysis 9
- Co-authors
- Aiping Lü (107 shared papers)Yuanyan Liu (38 shared papers)Pamela J. Green (5 shared papers)Zhiwen Cao (26 shared papers)Xiaojuan He (52 shared papers)Cheng Xiao (38 shared papers)Roy Parker (1 shared paper)Debrah M. Thompson (1 shared paper)
- Journals
- Frontiers in Pharmacology (15 papers)Evidence-based Complementary and Alternative Medicine (12 papers)International Journal of Molecular Sciences (9 papers)PLoS ONE (7 papers)Chinese Medicine (7 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Cheng Lü
261 papers receiving 8.8k citations
Cheng Lü's Hit Papers
Peers
Comparison fields: 5 of 170
- Complementary and alternative medicine 1.2k
- Cancer Research 1.1k
- Pharmacology 636
- Molecular Biology 4.3k
- Immunology 891
Countries citing papers authored by Cheng Lü
This map shows the geographic impact of Cheng Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Lü more than expected).
Fields of papers citing papers by Cheng Lü
This network shows the impact of papers produced by Cheng Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Lü. The network helps show where Cheng Lü may publish in the future.
Co-authors
The 25 scholars most cited alongside Cheng Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 268 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers Hit paper breakdown → | 2020 | 649 |
| 2 | 2009 | 494 | |
| 3 | 2008 | 463 | |
| 4 | 2012 | 308 | |
| 5 | 2015 | 253 | |
| 6 | 2007 | 196 | |
| 7 | 2010 | 180 | |
| 8 | 2006 | 178 | |
| 9 | 2019 | 131 | |
| 10 | 2008 | 113 | |
| 11 | 2018 | 105 | |
| 12 | 2016 | 104 | |
| 13 | 2017 | 102 | |
| 14 | 2019 | 95 | |
| 15 | 2022 | 95 | |
| 16 | 2016 | 91 | |
| 17 | 2009 | 90 | |
| 18 | 2009 | 87 | |
| 19 | 2009 | 87 | |
| 20 | 2020 | 83 |
About Cheng Lü
Cheng Lü is a scholar working on Molecular Biology, Complementary and alternative medicine, Immunology, Pharmacology and Oncology, having authored 268 papers that have together received 8.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (24 papers), Traditional Chinese Medicine Studies (21 papers), Natural Compounds in Disease Treatment (17 papers), Metabolomics and Mass Spectrometry Studies (17 papers), Pharmacological Effects of Natural Compounds (17 papers), Autoimmune and Inflammatory Disorders Research (11 papers), Cytokine Signaling Pathways and Interactions (11 papers) and Traditional Chinese Medicine Analysis (9 papers). The work is most often cited by research in Complementary and alternative medicine (1.2k citations), Cancer Research (1.1k citations), Pharmacology (636 citations), Molecular Biology (4.3k citations) and Immunology (891 citations). Cheng Lü has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Aiping Lü, Yuanyan Liu, Pamela J. Green, Zhiwen Cao, Xiaojuan He, Cheng Xiao, Roy Parker, Debrah M. Thompson, Youwen Chen and Miao Jiang. Their work appears in journals such as Frontiers in Pharmacology, Evidence-based Complementary and Alternative Medicine, International Journal of Molecular Sciences, PLoS ONE and Chinese Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.